文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

欧洲移民中的抗菌药物耐药性:系统综述与荟萃分析

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis.
PubMed 文献 · Lancet Infect Dis · 2018-05-17

该研究系统检索2000年1月1日至2017年1月18日文献,纳入23项观察性研究、2319名移民,采用随机效应模型合并分析。移民中任何抗菌药物耐药携带或感染合并患病率为25.4%(95%CI 19.1-31.8;I²=98%),难民和寻求庇护者(33.0%)高于其他移民群体(6.6%),高移民社区环境(33.1%)略高于医院内移民(24.3%)。未发现移民向宿主人群高水平传播耐药的证据。

要点

  • 移民中任何抗菌药物耐药携带或感染合并患病率为25.4%(95%CI 19.1-31.8;I²=98%)。
  • 难民和寻求庇护者耐药合并患病率33.0%,高于其他移民群体的6.6%。
  • 高移民社区环境耐药合并患病率33.1%,略高于医院内移民的24.3%。

核心结论

  • 移民在过境和欧洲宿主国面临有利于耐药出现的条件。
  • 难民和寻求庇护者及高移民社区环境中抗菌药物耐药增加,凸显改善生活条件、获得医疗保健及检测和适当高质量治疗耐药感染举措的需求。
  • 感染预防控制与抗生素监测方案需整合到医疗保健各方面,应覆盖所有移民群体,并针对移民前、中、后的抗菌药物耐药决定因素。
  • 未发现移民向宿主人群高水平传播耐药的证据。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、PubMed和Scopus,无语言限制,时间2000年1月1日至2017年1月18日。
  • 纳入报告移民中常见细菌病原体抗菌药物耐药的观察性研究原始数据,移民目的地为21个欧盟15国和欧洲经济区国家。
  • 纳入标准为报告移民人群实验室确诊抗生素耐药菌携带或感染数据。
  • 排除仅报告结核耐药的文章,排除以种族、父母出生国确定移民身份或未定义移民身份的文章,排除未按移民身份分层数据的文章。
  • 纳入23项观察性研究,共2319名移民;研究方案注册号PROSPERO CRD42016043681。

主要发现

  • 移民中任何抗菌药物耐药携带或感染合并患病率为25.4%(95%CI 19.1-31.8;I²=98%)。
  • 耐甲氧西林金黄色葡萄球菌合并患病率为7.8%(95%CI 4.8-10.7;I²=92%)。
  • 抗生素耐药革兰阴性菌合并患病率为27.2%(95%CI 17.6-36.8;I²=94%)。
  • 难民和寻求庇护者任何抗菌药物耐药携带或感染合并患病率为33.0%(95%CI 18.3-47.6;I²=98%),高于其他移民群体的6.6%(95%CI 1.8-11.3;I²=92%)。
  • 高移民社区环境抗生素耐药菌合并患病率为33.1%(95%CI 11.1-55.1;I²=96%),略高于医院内移民的24.3%(95%CI 16.1-32.6;I²=98%)。

关键数值与推荐

  • 任何抗菌药物耐药携带或感染合并患病率25.4%(95%CI 19.1-31.8;I²=98%)。
  • 耐甲氧西林金黄色葡萄球菌合并患病率7.8%(95%CI 4.8-10.7;I²=92%)。
  • 抗生素耐药革兰阴性菌合并患病率27.2%(95%CI 17.6-36.8;I²=94%)。
  • 难民和寻求庇护者合并患病率33.0%(95%CI 18.3-47.6;I²=98%)对比其他移民群体6.6%(95%CI 1.8-11.3;I²=92%)。
  • 高移民社区环境合并患病率33.1%(95%CI 11.1-55.1;I²=96%)对比医院内移民24.3%(95%CI 16.1-32.6;I²=98%)。

临床怎么用

  • 作者认为需改善生活条件、获得医疗保健,并采取举措促进过境和宿主国期间耐药感染的检测和适当高质量治疗。
  • 作者认为感染预防控制与抗生素监测方案需整合到医疗保健各方面,应覆盖所有移民群体,并针对移民前、中、后的抗菌药物耐药决定因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nellums LB, Thompson H, Holmes A, et al. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis. Lancet Infect Dis. 2018. PMID: 29779917. doi:10.1016/S1473-3099(18)30219-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。